{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:46:23Z","timestamp":1790127983522,"version":"4.0.1"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017270","name":"NeuroCure Exzellenzcluster","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>This study aimed to evaluate the association of neurofilament light chain (Nfl) with neuromuscular destruction and disease severity in the serum of patients with myasthenia gravis (MG).<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Sera from 134 patients with MG with varying degrees of disease severity and autoantibody (Abs) status were analyzed and compared to controls in a cross-sectional design. Prospectively, we additionally measured serum NfL (sNfl) levels in patients with MG longitudinally for up to 3 years. Based on linear regression, differences between patients and controls were assessed. With correlation coefficients and mixed linear regression, the association among sNfl levels, socio-demographics, disease activity (Quantitative Myasthenia Gravis (QMG) score and Myasthenia Gravis Activities of Daily Living (MG-ADL) scale), Abs-status (acetylcholine receptor antibody (AChR-Abs), muscle-specific receptor tyrosine kinase antibody (MuSK-Abs), lipoprotein-related protein 4 (LRP4), and seronegative), Abs titer, treatment regime (pyridostigmine, steroids, and immunosuppressive therapies), and thymectomy were investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>sNfl levels were higher in patients with MG compared to controls (median: 11.2 vs. 7.88), where sNfl levels were highest in anti-AChR-Abs positive patients (median 12.6), followed by anti-MuSK-Abs positive, anti-LRP4-Abs positive, and seronegative patients. Adjusting for age and sex, sNfl levels of patients with MG were on average 35% higher compared to controls (35.1, 95% CI: 8.4;68.3) and highest for patients with seronegative MG (44.35; 95% CI 16.47; 78.90). We found no relevant relationship between individual changes in sNfl and changes in QMG and MG-ADL scores.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>sNfl levels are higher in patients with MG than in controls but were not consistently associated with clinical severity. Thus, sNfl is not a suitable biomarker to monitor individual disease progression in patients with MG.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.1056322","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T06:57:38Z","timestamp":1673420258000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Serum neurofilament light chain in myasthenia gravis subgroups: An exploratory cohort and case\u2013Control study"],"prefix":"10.3389","volume":"13","author":[{"given":"Frauke","family":"Stascheit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Mergenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Hotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Lehnerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.nmd.2019.12.003","article-title":"Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids","volume":"30","author":"Tannemaat","year":"2020","journal-title":"Neuromuscular Disorders NMD."},{"key":"B4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e75091","DOI":"10.1371\/journal.pone.0075091","article-title":"Increased neurofilament light chain blood levels in neurodegenerative neurological diseases","volume":"8","author":"Gaiottino","year":"2013","journal-title":"PLoS ONE."},{"key":"B7","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00415-017-8730-6","article-title":"neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis","volume":"265","author":"Rossi","year":"2018","journal-title":"J Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","article-title":"Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis","volume":"16","author":"Byrne","year":"2017","journal-title":"Lancet Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e1231","DOI":"10.1212\/WNL.0000000000005261","article-title":"Clinical value of neurofilament and phospho-tau\/tau ratio in the frontotemporal dementia spectrum","volume":"90","author":"Meeter","year":"2018","journal-title":"Neurology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1212\/WNL.0000000000003154","article-title":"Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia","volume":"87","author":"Rohrer","year":"2016","journal-title":"Neurology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/nan.12511","article-title":"Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis","volume":"45","author":"Gille","year":"2019","journal-title":"Neuropathol Appl Neurobiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.parkreldis.2018.06.018","article-title":"Serum neurofilament light chain in progressive supranuclear palsy","volume":"56","author":"Donker Kaat","year":"2018","journal-title":"Parkinsonism Relat Disord."},{"key":"B13","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/jns.12279","article-title":"Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies","volume":"23","author":"Mariotto","year":"2018","journal-title":"J Peripher Nerv Syst."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.3389\/fneur.2021.723009","article-title":"Calprotectin in chronic inflammatory demyelinating polyneuropathy and variants\u2014a potential novel biomarker of disease activity","volume":"12","author":"Stascheit","year":"2021","journal-title":"Front Neurol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1212\/WNL.0000000000004932","article-title":"Plasma neurofilament light chain concentration in the inherited peripheral neuropathies","volume":"90","author":"Sandelius","year":"2018","journal-title":"Neurology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1002\/acn3.51207","article-title":"Ratio and index of Neurofilament light chain indicate its origin in Guillain-Barr\u00e9 Syndrome","volume":"7","author":"K\u00f6rtvelyessy","year":"2020","journal-title":"Ann Clin Transl Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.nmd.2019.03.009","article-title":"review of the histopathological findings in myasthenia gravis: Clues to the pathogenesis of treatment-resistance in extraocular muscles","volume":"29","author":"Europa","year":"2019","journal-title":"Neuromuscul Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1136\/jnnp.36.2.244","article-title":"Neurogenic muscle involvement in myasthenia gravis. A clinical and histopathological study","volume":"36","author":"Oosterhuis","year":"1973","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/WCO.0b013e3283572588","article-title":"Myasthenia and the neuromuscular junction","volume":"25","author":"Gilhus","year":"2012","journal-title":"Curr Opin Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/WCO.0b013e328364c079","article-title":"Myasthenia gravis and the neuromuscular junction","volume":"26","author":"Querol","year":"2013","journal-title":"Curr Opin Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.1172\/JCI66039","article-title":"Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis","volume":"123","author":"Shen","year":"2013","journal-title":"J Clin Invest."},{"key":"B22","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/nri916","article-title":"Unravelling the pathogenesis of myasthenia gravis","volume":"2","author":"Vincent","year":"2002","journal-title":"Nat Rev Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/MCO.0000000000000267","article-title":"Neuromuscular junction degeneration in muscle wasting","volume":"19","author":"Rudolf","year":"2016","journal-title":"Curr Opin Clin Nutr Metab Care."},{"key":"B24","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/nyas.13573","article-title":"Agrin and LRP4 antibodies as new biomarkers of myasthenia gravis","volume":"1413","author":"Yan","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e13195","DOI":"10.1111\/apha.13195","article-title":"The sympathetic nervous system regulates skeletal muscle motor innervation and acetylcholine receptor stability","volume":"225","author":"Rodrigues","year":"2019","journal-title":"Acta physiologica."},{"key":"B26","first-page":"123","article-title":"Cytoskeletal proteins at the cholinergic synapse: distribution of desmin, actin, fodrin, neurofilaments, and tubulin in Torpedo electric organ","volume":"38","author":"Walker","year":"1985","journal-title":"Eur J Cell Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1365-2990.2011.01178.x","article-title":"Loss of neurofilaments in the neuromuscular junction in a rat model of proximal axonopathy","volume":"38","author":"Soler-Mart\u00edn","year":"2012","journal-title":"Neuropathol Appl Neurobiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12974-018-1333-z","article-title":"Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica","volume":"15","author":"Duan","year":"2018","journal-title":"J Neuroinflammation."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-022-02493-6","article-title":"Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities","author":"Rose","year":"2022","journal-title":"Acta Neuropathol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society","volume":"263","author":"Melzer","year":"2016","journal-title":"J Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.bbcan.2012.10.003","article-title":"Review of S100A9 biology and its role in cancer","volume":"1835","author":"Markowitz","year":"2013","journal-title":"Biochim Biophys Acta."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac328","article-title":"The multifaceted role of neurofilament light chain protein in non-primary neurological diseases","author":"Abu-Rumeileh","year":"2022","journal-title":"Brain."},{"key":"B33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards task force of the medical scientific advisory board of the myasthenia gravis foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1212\/01.WNL.0000163988.28892.79","article-title":"Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity","volume":"64","author":"Bedlack","year":"2005","journal-title":"Neurology."},{"key":"B36","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s004150050585","article-title":"Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis","volume":"247","author":"Sharshar","year":"2000","journal-title":"J Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/CND.0b013e31824619d5","article-title":"The quantitative myasthenia gravis score: comparison with clinical, electrophysiological, and laboratory markers","volume":"13","author":"Barnett","year":"2012","journal-title":"J Clin Neuromuscul Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","article-title":"Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations","volume":"28","author":"Rissin","year":"2010","journal-title":"Nat Biotechnol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","article-title":"Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa","volume":"54","author":"Kuhle","year":"2016","journal-title":"Clin Chem Lab Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/brain\/awy154","article-title":"Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis","volume":"141","author":"Barro","year":"2018","journal-title":"Brain."},{"key":"B42","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann Neurol."},{"key":"B43","volume-title":"R: A language and Environment for Statistical Computing","year":"2021"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Software"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Software."},{"key":"B46","first-page":"1","volume-title":"Spearmanci: Jackknife Euclidean\/Empirical Likelihood Inference for Spearman Rho","author":"De Carvalho","year":"2018"},{"key":"B47","author":"Bakdash","year":"2022","journal-title":"Package \u201crmcorr\u201d"},{"key":"B48","unstructured":"2022"},{"key":"B49","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12974-022-02448-4","article-title":"Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients","volume":"19","author":"Nelke","year":"2022","journal-title":"J Neuroinflam."},{"key":"B50","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/joim.12163","article-title":"Pathogenic immune mechanisms at the neuromuscular synapse: the role of specific antibody-binding epitopes in myasthenia gravis","volume":"275","author":"Huijbers","year":"2014","journal-title":"J Intern Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"New England J Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/978-1-4615-1857-0_23","article-title":"Evidence for presynaptic damage in myasthenia gravis","volume":"363","author":"Lu","year":"1995","journal-title":"Adv Exp Med Biol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/jnnp-2018-318704","article-title":"Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis","volume":"90","author":"Verde","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B54","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/jns.12319","article-title":"Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy","volume":"24","author":"van Lieverloo","year":"2019","journal-title":"J Peripher Nerv Syst."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis","volume":"76","author":"Bridel","year":"2019","journal-title":"JAMA Neurol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s41467-020-14612-6","article-title":"Serum neurofilament light levels in normal aging and their association with morphologic brain changes","volume":"11","author":"Khalil","year":"2020","journal-title":"Nat Commun."},{"key":"B57","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/brain\/aws025","article-title":"Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice","volume":"135","author":"Klooster","year":"2012","journal-title":"Brain J Neurol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1365-2990.2008.00965.x","article-title":"Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR","volume":"35","author":"Martignago","year":"2009","journal-title":"Neuropathol Appl Neurobiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s00415-010-5823-x","article-title":"Comparison of muscle ultrastructure in myasthenia gravis with anti-MuSK and anti-AChR antibodies","volume":"258","author":"Cenacchi","year":"2011","journal-title":"J Neurol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"965","DOI":"10.29271\/jcpsp.2021.08.965","article-title":"Relationship between Low and High Anti-acetylcholine receptor antibody titers and clinical severity in myasthenia gravis","volume":"31","author":"Ullah","year":"2021","journal-title":"J Coll Physicians Surg Pak."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e02203","DOI":"10.1002\/brb3.2203","article-title":"No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: A systematic retrospective study involving 67 patients","volume":"11","author":"Wang","year":"2021","journal-title":"Brain Behav."},{"key":"B63","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/mus.23944","article-title":"Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?","volume":"49","author":"Sanders","year":"2014","journal-title":"Muscle Nerve."},{"key":"B64","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/ene.12270","article-title":"Antibodies to clustered acetylcholine receptor: expanding the phenotype","volume":"21","author":"Devic","year":"2014","journal-title":"Eur J Neurol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain J Neurol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.expneurol.2015.01.011","article-title":"Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases","volume":"270","author":"Rodriguez Cruz","year":"2015","journal-title":"Exp Neurol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00401-020-02147-5","article-title":"Complement deposition at the neuromuscular junction in seronegative myasthenia gravis","volume":"139","author":"Hoffmann","year":"2020","journal-title":"Acta Neuropathol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1007\/s00415-022-11023-z","article-title":"Seronegative myasthenic crisis: a multicenter analysis","volume":"269","author":"Mergenthaler","year":"2022","journal-title":"J Neurol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.3389\/fneur.2018.01167","article-title":"Diagnostic and prognostic performance of neurofilaments in ALS","volume":"9","author":"Poesen","year":"2018","journal-title":"Front Neurol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1056322\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T06:57:47Z","timestamp":1673420267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1056322\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":69,"alternative-id":["10.3389\/fneur.2022.1056322"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.1056322","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,11]]},"article-number":"1056322"}}